Latest News and Press Releases

Disease modifying mechanism of action: short treatment course results in significant and durable clinical response in psoriasis patients si-544 is the first highly potent and selective Kv1.3 blocker...

Partial remissions and complete metabolic responses in PD-1/PD-L1-resistant cancersFirst-in-class multi-checkpoint inhibitor with robust efficacy and safetyCombination arm with pembrolizumab...

-- Existing and new investors joining forces to support the accelerated development of Omnix´s novel, first-in-class antimicrobials pipeline -- Funding underlines urgent global need for novel,...

- Novel, disease-modifying treatment option for Pulmonary Arterial Hypertension (PAH), an orphan indication with a significant unmet medical need Kiel, GERMANY, September 8, 2025 – tiakis Biotech AG...

Leading international experts to support clinical development of BellaSeno´s pioneering resorbable breast implantsPivotal clinical trial to be initiated shortly Leipzig, Germany / Brisbane,...

Funding combines equity investment and convertible loanFocus on best-in-class, clinical-stage peanut allergen neutralizing antibody Further potential for developing Mabylon’s discovery and...

European Medicines Agency recognizes potential of lead compound MP1032 in addressing a high unmet medical need in Duchenne Muscular Dystrophy (DMD)Designation is paving the way for safer long-term...

Funding supports market launch of platform for clinical and commercial applicationsCompany targets Euro 15 billion in silico trials market and ICU decision support Munich, Germany – July 2, 2025 --...

Heat-triggered release mechanism unequivocally confirmedFavorable safety profile with good tolerability Signs of encouraging clinical activity in heavily pre-treated patients including meaningful...

Berlin, Germany – June 17th, 2025 – Captain T Cell GmbH, a biotech company developing next-generation TCR-based cell therapies for patients with solid tumors, today announced that it has been selected...